Lilly’s 2021 Double-Digit Growth Comes From COVID-19 Drugs, New Products
Prevail Purchase For $880m Adds Gene Therapy Capabilities
Most of Lilly’s 2021 gains will come from its newer products, but sales of COVID-19 treatments added $500m to the company’s 2020 revenue guidance and may total $1bn-$2bn next year.
